Page 297 - Binder2

For conditions like celiac disease, inflammatory bowel
disease, and food allergies, oral plant-based biologics are
under active investigation—often in preclinical or Phase 1
studies. But already, they’re showing signs that they can
reduce inflammation, promote regulatory immune cells,
and offer site-specific action without the collateral damage
of whole-body immunosuppression.

Patients as Partners in Innovation

Perhaps most inspiring is how these patients are not just
recipients—they’re co-creators. Every compassionate-use
request, every trial enrollment, every symptom diary is a
contribution to a new model of medicine. They are testing
more than molecules. They are testing a philosophy: that
medicine can be gentler, greener, more integrated with
daily life.

They are proof that the edible biologic is not a gimmick.
It’s a solution. And for some, it’s already working.

These stories are not statistical endpoints. They are
beginnings.
They remind us why we build new drug platforms—not to
dazzle with novelty, but to serve the people who need them
most.
One leaf. One dose. One life changed at a time.

295